Jun 24, 2024, 01:48
Novel PARP inhibitor saruparib in metastatic hormone-sensitive prostate cancer
UroToday shared a post on X: .
“The EvoPAR-Prostate 01 Trial: Novel PARP inhibitor saruparib in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC).
Neeraj Agarwal from Huntsman Cancer Institute and Zach Klaassen from Georgia Cancer Center discuss this new PARP inhibitor combined with ARPI in both biomarker-positive and negative populations.”
Proceed to the video.
Source: UroToday/X